Unknown statusInterventionalPhase 1Last updated Sep 29, 2021

A Study of of HOT1030 in Patients With Advanced Solid Tumors

A Phase 1, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HOT1030 in Patients With Advanced Solid Tumors

Overview

ClinicalTrials.gov ID: NCT05060263
Lead Sponsor: Huabo Biopharm Co., Ltd.INDUSTRY
Brief Summary: A Phase 1, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HOT-1030 in Patients with Advanced Solid Tumors
Study Type: Interventional

Status

Overall Status: Unknown status
Start Date: Mar 12, 2021Actual
Primary Completion Date: Jun 30, 2023Estimated
Completion Date: Jun 30, 2023Estimated

Study Record Dates

First Submitted: Mar 26, 2021
First Submitted that Met QC Criteria: Sep 17, 2021
First Posted: Sep 29, 2021Actual
Last Update Submitted that Met QC Criteria: Sep 17, 2021
Last Update Posted: Sep 29, 2021Actual
Last Verified: Sep 2021

NCT05911464Recruiting

A Phase I Study of HS-10386 in Participants With Advanced Solid Tumors

NCT07554196Completed

A Phase 1 Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HH-101 in Patients With Advanced Solid Tumors

NCT04060511Completed

A Study of HS-10342 in Patients With Advanced Solid Tumor

NCT03398720Unknown status

Safety and Tolerability of HTI-1066 in Subjects With Advanced Solid Tumors

NCT05417321Recruiting

A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors

NCT05378178Unknown status

A PhaseⅠStudy of HS-10381 in Patients With Advanced Solid Tumors